<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T04:41:28Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6438729" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6438729</identifier>
        <datestamp>2019-09-13</datestamp>
        <setSpec>nihpa</setSpec>
        <setSpec>pmc-open</setSpec>
        <setSpec>manuscript</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-journal-id">0410462</journal-id>
              <journal-id journal-id-type="pubmed-jr-id">6011</journal-id>
              <journal-id journal-id-type="nlm-ta">Nature</journal-id>
              <journal-id journal-id-type="iso-abbrev">Nature</journal-id>
              <journal-title-group>
                <journal-title>Nature</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0028-0836</issn>
              <issn pub-type="epub">1476-4687</issn>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6438729</article-id>
              <article-id pub-id-type="pmcid">PMC6438729</article-id>
              <article-id pub-id-type="pmc-uid">6438729</article-id>
              <article-id pub-id-type="pmid">30867592</article-id>
              <article-id pub-id-type="pmid">30867592</article-id>
              <article-id pub-id-type="doi">10.1038/s41586-019-1012-y</article-id>
              <article-id pub-id-type="manuscript">nihpa1521555</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Efficacy of MEK Inhibition in Patients with Histiocytic Neoplasms</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Diamond</surname>
                    <given-names>Eli L.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                  <xref ref-type="aff" rid="A10">10</xref>
                  <xref rid="FN1" ref-type="author-notes">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Durham</surname>
                    <given-names>Benjamin H.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A2">2</xref>
                  <xref ref-type="aff" rid="A3">3</xref>
                  <xref rid="FN1" ref-type="author-notes">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ulaner</surname>
                    <given-names>Gary A</given-names>
                  </name>
                  <xref ref-type="aff" rid="A4">4</xref>
                  <xref ref-type="aff" rid="A10">10</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Drill</surname>
                    <given-names>Esther</given-names>
                  </name>
                  <xref ref-type="aff" rid="A5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Buthorn</surname>
                    <given-names>Justin</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ki</surname>
                    <given-names>Michelle</given-names>
                  </name>
                  <xref ref-type="aff" rid="A3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bitner</surname>
                    <given-names>Lillian</given-names>
                  </name>
                  <xref ref-type="aff" rid="A3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cho</surname>
                    <given-names>Hana</given-names>
                  </name>
                  <xref ref-type="aff" rid="A3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Young</surname>
                    <given-names>Robert J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Francis</surname>
                    <given-names>Jasmine H</given-names>
                  </name>
                  <xref ref-type="aff" rid="A6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rampal</surname>
                    <given-names>Raajit</given-names>
                  </name>
                  <xref ref-type="aff" rid="A7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lacouture</surname>
                    <given-names>Mario</given-names>
                  </name>
                  <xref ref-type="aff" rid="A8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Brody</surname>
                    <given-names>Lynn A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ozkaya</surname>
                    <given-names>Neval</given-names>
                  </name>
                  <xref ref-type="aff" rid="A2">2</xref>
                  <xref ref-type="aff" rid="A11">11</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dogan</surname>
                    <given-names>Ahmet</given-names>
                  </name>
                  <xref ref-type="aff" rid="A2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rosen</surname>
                    <given-names>Neal</given-names>
                  </name>
                  <xref ref-type="aff" rid="A7">7</xref>
                  <xref ref-type="aff" rid="A9">9</xref>
                  <xref ref-type="aff" rid="A10">10</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Iasonos</surname>
                    <given-names>Alexia</given-names>
                  </name>
                  <xref ref-type="aff" rid="A5">5</xref>
                  <xref ref-type="aff" rid="A10">10</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Abdel-Wahab</surname>
                    <given-names>Omar</given-names>
                  </name>
                  <xref ref-type="aff" rid="A3">3</xref>
                  <xref ref-type="aff" rid="A7">7</xref>
                  <xref ref-type="aff" rid="A10">10</xref>
                  <xref rid="CR1" ref-type="corresp">**</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hyman</surname>
                    <given-names>David M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A7">7</xref>
                  <xref ref-type="aff" rid="A10">10</xref>
                  <xref rid="CR1" ref-type="corresp">**</xref>
                </contrib>
              </contrib-group>
              <aff id="A1"><label>1</label>Dept. of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065</aff>
              <aff id="A2"><label>2</label>Dept. of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065</aff>
              <aff id="A3"><label>3</label>Human Oncology and Pathogenesis Program, Dept. of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065</aff>
              <aff id="A4"><label>4</label>Dept. of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065</aff>
              <aff id="A5"><label>5</label>Dept. of Epidemiology and Statistics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065</aff>
              <aff id="A6"><label>6</label>Ophthalmic Oncology Service, Dept. of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065</aff>
              <aff id="A7"><label>7</label>Dept. of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065</aff>
              <aff id="A8"><label>8</label>Dermatology Service, Dept. of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065</aff>
              <aff id="A9"><label>9</label>Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065</aff>
              <aff id="A10"><label>10</label>Weill Cornell Medical College, New York, NY, 10065</aff>
              <aff id="A11"><label>11</label>Laboratory of Pathology, National Cancer Institute, Bethesda, MD</aff>
              <author-notes>
                <fn fn-type="con" id="FN1">
                  <label>*</label>
                  <p id="P1">These authors contributed equally to this work.</p>
                </fn>
                <fn fn-type="con" id="FN2">
                  <p id="P2"><bold>Author contributions</bold> ELD, OAW, and DMH designed the study. MK, LB, and HC processed all patient material for isolation of DNA and RNA for genomic analyses. BHD cloned all cDNAs and performed <italic>in vitro</italic> studies of their effects on cell growth and signaling under the supervision of NR and OAW. BHD also analyzed genomic data under the supervision of OAW. JB collected data and samples for processing by MK, LB, and HC. ELD, JHF, RR, ML, and LAB enrolled and treated the patients. ED and AI performed statistical analyses. GAU and EJY evaluated all radiographic studies. ELD, BHD, NO, AD, OAW, and DMH analyzed the clinical and laboratory data. ELD, BHD, OAW, and DMH prepared the manuscript with help from all co-authors.</p>
                </fn>
                <corresp id="CR1"><label>**</label>Co-corresponding. <bold>Correspondence:</bold> Omar Abdel-Wahab, Memorial Sloan Kettering Cancer, 1275 York Avenue, New York, NY 10065, +16468883487, <email>abdelwao@mskcc.org</email>, David M. Hyman,, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, +16468884544, <email>hymand@mskcc.org</email></corresp>
              </author-notes>
              <pub-date pub-type="nihms-submitted">
                <day>14</day>
                <month>2</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>13</day>
                <month>3</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>3</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>13</day>
                <month>9</month>
                <year>2019</year>
              </pub-date>
              <volume>567</volume>
              <issue>7749</issue>
              <fpage>521</fpage>
              <lpage>524</lpage>
              <!--elocation-id from pubmed: 10.1038/s41586-019-1012-y-->
              <permissions>
                <license license-type="permissions-link">
                  <license-p><bold>Author Information</bold> Reprints and permission information is available at <ext-link ext-link-type="uri" xlink:href="http://www.nature.com/reprints">www.nature.com/reprints</ext-link>.</license-p>
                </license>
                <license>
                  <license-p>Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:<uri xlink:type="simple" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</uri></license-p>
                </license>
              </permissions>
              <abstract id="ABS1">
                <p id="P3">Histiocytic neoplasms are a heterogeneous group of clonal hematopoietic disorders marked by diverse mutations in the mitogen-activated protein kinase (MAPK) pathway.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup> For the 50% of histiocytosis patients with BRAFV600-mutations<sup><xref rid="R3" ref-type="bibr">3</xref>–<xref rid="R5" ref-type="bibr">5</xref></sup>, RAF inhibition is highly efficacious and has dramatically altered the natural history of the disease.<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref></sup> Conversely, no standard therapy exists for the remaining 50% of patients lacking BRAFV600-mutations. While ERK dependence has been hypothesized to be a consistent feature across histiocytic neoplasms, this remains clinically unproven and many kinase mutations found in these patients have not been biologically characterized. We set out to evaluate ERK dependence in histiocytoses through a proof-of-concept clinical trial of the oral MEK1/2 inhibitor cobimetinib in patients with histiocytoses. Patients were enrolled regardless of tumor genotype. In parallel, novel MAPK alterations identified in treated patients were characterized for their ability to activate ERK. In 18 treated patients, the overall response rate (ORR) was 89% (90% CI: 73–100). Responses were durable, with no acquired resistance to date. At one year, 100% of responses were ongoing, and 94% of patients remained progression-free. Efficacy was observed regardless of genotype with responses achieved in patients with ARAF, BRAF, RAF1, NRAS, KRAS, MEK1, and MEK2 mutations. Consistent with observed responses, characterization of the novel mutations identified in treated patients confirmed them to be activating. Collectively, these data demonstrate that histiocytic neoplasms are characterized by remarkable dependence on MAPK signaling and, consequently, responsiveness to MEK inhibition. These results extend the benefits of molecularly targeted therapy to the entire spectrum of patients with histiocytosis.</p>
              </abstract>
            </article-meta>
          </front>
          <body>
            <p id="P4">Based on the success of targeting BRAFV600 in the two most common histiocytic neoplasms, Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD), efforts were undertaken to identify potential genomic drivers of disease in patients that do not harbor this mutation. These genomic studies of histiocytoses have identified a remarkable diversity of both previously characterized as well as novel alterations involving multiple components of the MAPK pathway<sup><xref rid="R8" ref-type="bibr">8</xref>–<xref rid="R13" ref-type="bibr">13</xref></sup>. Interestingly, many of the recurrent mutations in histiocytic neoplasms occur in MAPK pathway genes such as ARAF, RAF1, MEK1, and MEK2 that are rarely, if ever, mutated in other malignancies. Consequently, many of these mutations have not been biologically characterized. Consistent with the underlying hypothesis that these non-BRAFV600 mutations likely drive histiocytic neoplasms, drugs that inhibit both MEK1/2, kinases immediately downstream of BRAF, have been shown in case reports to evoke responses in these patients<sup><xref rid="R14" ref-type="bibr">14</xref>–<xref rid="R16" ref-type="bibr">16</xref></sup>. Despite these findings, the true extent and durability of response, as well as safety of MEK1/2 inhibition across a wider range of histologic and molecular subsets of histiocytosis remains unknown.</p>
            <p id="P5">To formally evaluate the therapeutic potential of MEK1/2 inhibition in histiocytic neoplasms, we conducted a Phase II study of the MEK1/2 inhibitor, cobimetinib, in adult patients with histiocytoses of any mutational status (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link>, NCT02649972). Consistent with common clinical practice for response assessment in these disorders<sup><xref rid="R17" ref-type="bibr">17</xref>–<xref rid="R19" ref-type="bibr">19</xref></sup>, the primary endpoint was response rate (complete response + partial response) as determined by fluorodeoxyglucose (FDG)-positron emission tomography (PET). To provide additional corroboration of treatment efficacy, a key secondary end point included response by CT/MRI per RECIST version 1.1<sup><xref rid="R20" ref-type="bibr">20</xref></sup>. Simultaneously, we utilized this clinical trial as a platform to perform real-time patient-driven discovery of novel MAPK pathway alterations through biological characterization of novel alterations identified through comprehensive profiling of patient samples.</p>
            <p id="P6">A total of 18 patients were enrolled and treated (<xref rid="T1" ref-type="table">Extended Data Table 1</xref>). Patients had a variety of histiocytic neoplasms including ECD (n=12 patients), LCH (n=2), Rosai-Dorfman disease (n=2), and mixed histiocytosis (n=2). Eighty-nine percent (16/18) of patients had received at least one prior therapy and 56% (10/18) two or more prior therapies. Five patients (28%) had an ECOG performance status of ≥2.</p>
            <p id="P7">At the time of the pre-planned primary efficacy analysis performed using a data-cutoff of April 25, 2018, the ORR was 89% (90% one-sided confidence interval [CI], 73 to 100), as determined by PET response criteria (<xref rid="F1" ref-type="fig">Fig. 1a</xref>). Overall, 72% of the patients (13 patients) had a complete response, 17% (3) partial response, 6% (1) stable disease, none (0) had progressive disease, and 6% (1) could not be evaluated owing to early withdrawal for clinical deterioration (<xref rid="T2" ref-type="table">Extended Data Table 2</xref>). All patients were accounted for in the analysis, including the patient who could not be evaluated, per protocol (counted as non-responder). Responses occurred at all sites of disease including the central nervous system, a site associated with morbidity and mortality<sup><xref rid="R21" ref-type="bibr">21</xref></sup>. According to CT/MRI-based RECIST v1.1 criteria, the ORR was 57% (90% one-sided CI: 37 to 100), in the 14 of 18 patients evaluable by these criteria (<xref rid="F3" ref-type="fig">Extended Data Fig. 1</xref>). The median time to best response according to PET response criteria was 3.2 months (range, 1.6 to 15.9, <xref rid="F1" ref-type="fig">Fig. 1b</xref>). At the time of data analysis, 50% (9/18) of patients remained on protocol therapy, and an additional 17% (3/18), all in complete response, had elected to withdraw and continue to receive MEK inhibitory therapy off-label.</p>
            <p id="P8">The median duration of response and the median progression-free survival had not yet been reached after a median follow up of 11.9 months (range, 4.6 to 26.4) (<xref rid="F1" ref-type="fig">Fig. 1c</xref>, <xref rid="F4" ref-type="fig">Extended Data Fig. 2</xref>). No responding patient has progressed to date. Among those who discontinued treatment for any reason, median time on treatment was 11.9 months (range, 1.6 to 23.7). At one year, 100% of responses were ongoing, and 94% of patients remained progression-free.</p>
            <p id="P9">The adverse events observed are shown in <xref rid="T3" ref-type="table">Extended Data Table 3</xref>-<xref rid="T4" ref-type="table">4</xref>. Overall, the safety profile was consistent with prior studies of cobimetinib<sup><xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R23" ref-type="bibr">23</xref></sup>. Of the 18 treated patients, 10 (56%) had their cobimetinib dose reduced at least once. Adverse events leading to dose reduction included ejection fraction decrease (in 5 patients), rash (in 2), diarrhea (in 2), and fatigue and thrombocytopenia (in 1 each). In all cases, patients whose doses were reduced had their best response maintained at the lower dose. One patient permanently discontinued cobimetinib due to an adverse event (central retinal vein occlusion). Another patient with extensive baseline histiocytic lung involvement died of pneumonia, deemed unrelated to cobimetinib, prior to first response assessment and was counted as a non-responder per protocol.</p>
            <p id="P10">To identify the MAPK pathway alterations present in each patient, a variety of sequencing assays were performed according to tissue availability (<xref rid="T5" ref-type="table">Extended Data Table 5</xref>). In some cases, MAPK mutations were defined on the basis of sequencing performed at an outside commercial laboratory. At least one mutation involving the MAPK pathway was identified in 83% (15/18) of patients. Patients harbored a variety of MAPK pathway mutations involving BRAF (n=5 with V600, n=1 with non-V600), MEK1 (n=4), KRAS (n=3), ARAF (n=2), RAF1 (n=1), MEK2 (n=1), and NRAS (n=1). Two patients had mutations involving more than one gene in the MAPK pathway. Three patients had unknown mutational status, including one case in which sequencing of two separate biopsies failed due to low tumor cellularity. Responses were observed across genotypes, as well as in 2 of 3 patients with unknown mutations (<xref rid="F1" ref-type="fig">Fig. 1a</xref>). While several alterations detected here (including several in BRAF, ARAF, and MEK1) are known to be recurrent in histiocytoses, RAF1 mutations have not been previously described in histiocytoses, and the specific RAF1, MEK2, and BRAF indel mutations identified here have not been functionally characterized in any setting (<xref rid="F6" ref-type="fig">Extended Data Fig. 4</xref>). We therefore evaluated the transforming potential, ability to activate ERK, and responsiveness to cobimetinib <italic>in vitro</italic> for each of these three novel mutations. In each case, the MEK2 Y134H, BRAF N486_T491delinsK, and RAF1 K106N mutations robustly led to cytokine independence in Ba/F3 cells (a murine IL3-dependent, pro-B cell line) and activated ERK signaling while wild-type MEK2, RAF1, and BRAF did not (<xref rid="F2" ref-type="fig">Fig. 2a-f</xref>). Moreover, expression of each mutation sensitized Ba/F3 cells to cobimetinib while parental Ba/F3 cells remained relatively insensitive to cobimetinib (<xref rid="F2" ref-type="fig">Fig. 2g</xref>). These <italic>in vitro</italic> responses were consistent with the clinical responses seen in patients bearing these same alleles on the trial (<xref rid="F1" ref-type="fig">Fig. 1a-b</xref> and <xref rid="F2" ref-type="fig">2a,c,e</xref>).</p>
            <p id="P11">In this study, cobimetinib, a selective inhibitor of MEK1/2, had marked and durable activity in adults with histiocytic neoplasms. Responses to cobimetinib were observed across histiocytosis subtypes and tumor genotypes, although consistent with the expectations for a study mandating adult patients to have either refractory or multiorgan disease, ECD constituted the majority (67%) of treated patients. Therefore, some caution is warranted when applying these findings to all patients with histiocytosis. The efficacy of cobimetinib across MAPK genotypes here is remarkable given that single-agent efficacy of MEK1/2 inhibitors in other MAPK pathway altered solid tumors has generally been disappointing<sup><xref rid="R24" ref-type="bibr">24</xref></sup>. Indeed, prior work has shown that RAS mutations vary in their dependence on MEK1/2<sup><xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup>. Similarly, preclinical studies have previously suggested that several MEK1/2 mutations, including some observed in patients treated here, would confer resistance to MEK1/2 inhibition<sup><xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R28" ref-type="bibr">28</xref></sup>. Importantly, responses to cobimetinib were not only nearly universal but also durable and, in fact, no acquired resistance has been observed to date. This finding suggests that histiocytic neoplasms may lack the ability to adapt to the tonic MEK1/2 inhibition and suggest that cobimetinib may dramatically alter the natural history of these disorders. It is noteworthy that similar efficacy and durability of response was previously observed with vemurafenib in the subset of histiocytic neoplasms that harbor BRAFV600 mutations<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref></sup>.</p>
            <p id="P12">Overall, our data demonstrate that cobimetinib results in consistent and durable responses across clinical and genetic subtypes of histiocytic neoplasms, an area of unmet medical need. These findings further suggest that histiocytic neoplasms are collectively characterized by dependence on MAPK pathway signaling and, consequently, responsiveness to MEK1/2 inhibition.</p>
            <sec id="S1">
              <title>Methods</title>
              <sec id="S2">
                <title>Patients</title>
                <p id="P13">Eligible patients had a histiocytic neoplasm, were age 16 or older, had an Eastern Cooperative Oncology Group performance-status score of 0 to 3 (on a scale from 0 to 5, with higher scores indicating greater disability), and had adequate major organ function. Patients were required to have one of the following: (1) multi-system disease, (2) disease that was recurrent or refractory to standard therapies, or (3) single-organ system disease deemed unlikely to benefit from conventional therapies (for example, central nervous system or cardiac infiltration). Patients with tumors that were wild type for BRAF V600 were eligible. Patients with BRAF V600-mutations were eligible only in the setting of (1) intolerance or resistance to prior BRAF inhibitor therapy, or (2) the inability to access BRAF inhibitor therapy. Complete eligibility criteria are available in the study protocol (see <xref rid="SD2" ref-type="supplementary-material">Supplemental Information</xref>).</p>
                <p id="P14">The protocol was approved by the institutional review board at Memorial Sloan Kettering Cancer Center, complied with the International Ethical Guidelines for Biomedical Research Involving Human Subjects, Good Clinical Practice guidelines, and the Declaration of Helsinki. All patients provided written informed consent.</p>
              </sec>
              <sec id="S3">
                <title>Study Design and Treatment</title>
                <p id="P15">The primary endpoint was the overall response rate (CR + PR) by PET response criteria (see <xref rid="SD2" ref-type="supplementary-material">Supplementary Information</xref>). These criteria were previously utilized for analysis of vemurafenib efficacy in BRAF V600-mutant histiocytic disorders, a dataset that formed the basis of regulatory authorization for this indication in the United States<sup><xref rid="R7" ref-type="bibr">7</xref></sup>. PET responses were investigator assessed by a radiologist with dual board-certification in diagnostic radiology and nuclear medicine (GU). Secondary endpoints included duration of response and progression-free survival based on PET criteria, safety and response rate according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Patients received cobimetinib at a starting dose of 60mg daily for 21 days of each 28 day cycle.</p>
              </sec>
              <sec id="S4">
                <title>Study Assessments</title>
                <p id="P16">Tumor assessments were performed by means of PET/CT, MRI, or clinical measurement with calipers in the case of cutaneous lesions, at baseline, every 8 weeks for 6 months, and every 16 weeks thereafter until disease progression. Adverse events were assessed from the date that informed consent was obtained until at least 28 days after the last dose of cobimetinib was administered. Adverse events were classified and graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 (<ext-link ext-link-type="uri" xlink:href="https://evs.nci.nih.gov/ftp1/CTCAE/About.html">https://evs.nci.nih.gov/ftp1/CTCAE/About.html</ext-link>).</p>
              </sec>
              <sec id="S5">
                <title>Study Oversight</title>
                <p id="P17">The study was designed jointly by the first and last authors. The investigators collected and analyzed the data. All authors had access to the data, and the first and last authors wrote the first draft of the manuscript. All the authors were involved in the data analysis and manuscript preparation. All the authors vouch for the completeness and accuracy of the data and analyses and for the adherence to the study protocols. All the authors made the decision to submit the manuscript for publication. Data, safety, and quality monitoring were performed by the Memorial Sloan Kettering Cancer Center Data and Safety Monitoring Committee. All data elements were de-identified by removing identifying characteristics and replacing them with code numbers 1 through 18.</p>
              </sec>
              <sec id="S6">
                <title>Statistical Analysis</title>
                <p id="P18">All the analyses were conducted in accordance with the pre-specified statistical plan as outlined in the protocol unless otherwise indicated (see <xref rid="SD2" ref-type="supplementary-material">Supplementary Information</xref>). The primary analysis, presented here, was performed at the time the first 18 consecutively enrolled patients to receive cobimetinib were evaluable for response or discontinued protocol therapy (<xref rid="F6" ref-type="fig">Extended Data Fig. 4</xref>). Patients who discontinued therapy without a post-baseline tumor assessment were considered to be non-responders. Assuming a binary endpoint of PET response (complete response or partial response versus neither), we estimated that a sample of 18 patients would provide the study with 90% power to test the hypothesis that the response rate is promising (defined as 35% or higher) against a non-promising rate of 10% or lower. Using an exact, one-sample test for binomial proportion, with Type I error=10% and Type II error=10%, the above rates provided a sample size of 18 patients; if at least 4/18 responses were observed then this would be considered a positive study (i.e. conclude that the true response rate is &gt;10%). Ruling out a lower limit of 10% for the overall response rate was considered to be clinically meaningful in light of the poor response to treatment in the context of multi-system or refractory histiocytosis. Secondary end points included overall response rate according to RECIST version 1.1 and duration of response and progression-free survival (PFS) based on PET criteria as estimated by the Kaplan-Meier method. Duration of response was defined beginning with the date of response and ending with the date of progression, beginning of an alternative anti-cancer (non-MEK inhibitor) therapy, or death, or date of last follow up. PFS was defined as the time from the first day of study treatment, until the first documented progression of disease or death from any cause, whichever occurs first, or date of last follow up. Patients who discontinued cobimetinib, in the absence of progression, in order to receive an off-label MEK inhibitor were censored for DOR and PFS at the at the last follow up date. These patients were also considered to be continuing treatment for the purposes of calculating treatment duration exposure. FDG-PET and RECIST responses were investigator-assessed. All patients who received at least one dose of cobimetinib were included in both the efficacy and safety analysis set. All statistical analyses were performed with R, version 3.5.0 (<ext-link ext-link-type="uri" xlink:href="http://www.r-project.org/">http://www.R-project.org/</ext-link>)</p>
              </sec>
              <sec id="S7">
                <title>Genomic Analysis</title>
                <p id="P19">In patients with samples available for centralized testing, genomic analyses for MAPK pathway mutations was performed on DNA extracted from histiocyte tissue biopsies using a variety of assays, most commonly targeted exon sequencing using MSK-IMPACT or Heme-PACT<sup><xref rid="R29" ref-type="bibr">29</xref>,<xref rid="R30" ref-type="bibr">30</xref></sup>. Targeted RNA sequencing was also utilized for the purposes of detecting gene fusions using the Archer FusionPlex Custom Solid Panel<sup><xref rid="R31" ref-type="bibr">31</xref></sup>. Whole exome sequencing was also performed, based on DNA adequacy, using fingernails as germline control per previously described methods<sup><xref rid="R8" ref-type="bibr">8</xref></sup>. In some cases, different biopsies from the same individual were utilized for different genomic assays. Histiocytic neoplasms are routinely characterized by low tumor cellularity often resulting in low variant allele fractions for established driver mutations such as BRAF V600 <sup><xref rid="R8" ref-type="bibr">8</xref></sup>. As such, sequences from samples in which no MAPK pathway mutation was called using established pipelines developed and optimized for use in more cellular solid tumors were manually curated and high confidence mutations with lower read support salvaged.</p>
              </sec>
              <sec id="S8">
                <title>Plasmids</title>
                <p id="P20">To investigate the functional roles and the activation of oncogenic signaling pathways, we cloned the <italic>MAP2K2</italic> Y134H, <italic>RAF1</italic> K106N, and <italic>BRAF</italic> N486_T491delinsK mutations and expressed them in Ba/F3 cells. MSCV-based expression vectors with GFP and the full-length <italic>MAP2K2</italic>, <italic>RAF1</italic>, and <italic>BRAF</italic> wild type were used as controls. Mutational constructs were cloned into the MSCV-IRES-GFP backbone and checked by digestion and sequencing.</p>
              </sec>
              <sec id="S9">
                <title>Western Blotting</title>
                <p id="P21">Anti-phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) (no. 9101), anti-p44/42 MAPK (ERK1/2) (137F5) (no. 4695), anti-MEK1/2 (47E6) (no. 9126), anti-B-Raf (D9T6S) (no. 14814), anti-c-Raf (D4B3J) (no. 53745), as well as the secondary antibodies anti-rabbit IgG-HRP (no. 7076) and anti-mouse IgG-HRP (no. 7074) were purchased from Cell Signaling Technology. Anti-β-Actin (A5441) was purchased from Sigma-Aldrich®. Cell lysates were prepared in RIPA buffer supplemented with Halt protease and phosphatase inhibitor cocktail (Thermo Scientific). Equal amounts of protein, as measured by the BRADFORD protein assay, were resolved in 4–12% Bis-Tris NuPage gradient gels (Life Technologies), and transferred electrophoretically on a polyvinylidene difluoride 0.45-m membrane. Membranes were blocked for 1 h at room temperature in 5% bovine serum albumin (BSA) in TBST before being incubated overnight at 4°C with the primary antibodies. All primary antibodies were diluted 1:1,000 in 5% BSA in TBST, except anti-β-actin, which was diluted 1:5,000 in 5% BSA in TBST. After three washes of 10 min in TBST, secondary antibodies were diluted 1:2,000 in 5% BSA in TBST and incubated for 1 h at room temperature. After another three washes in TBST, detection of the signal was achieved by incubating the membrane on an ECL solution from Millipore and exposure on autoradiography films from Denville Scientific (Metuchen, NJ, USA).</p>
              </sec>
              <sec id="S10">
                <title>Drug Studies</title>
                <p id="P22">Cobimetinib was purchased from Selleckchem. Drug studies were conducted <italic>in vitro</italic> using FACS-sorted, DAPI − eGFP + Ba/F3 cells that stably expressed the MIGII-EV, MIGII-MEK2<sup>Y134H</sup>, MIGII-RAF1 K106N and MIGII-BRAF N486_T491delinsK constructs using the CellTiter-Glo Luminescent Cell Viability Assay from Promega Corporation, according to the manufacturer’s instructions. The MIGII-MEK2 Y134H, MIGII-RAF1 K106N, and MIGII-BRAF N486_T491delinsK, FACS-sorted Ba/F3 cells were maintained in RPMI + 10% FBS + penicillin and streptomycin media without murine IL3. Meanwhile, MIGII-EV was maintained in RPMI + 10% FBS + penicillin and streptomycin with recombinant murine IL3 (1 ng/mL).</p>
              </sec>
              <sec sec-type="data-availability" id="S11">
                <title>Data Availability</title>
                <p id="P23">All datasets generated during and/or analyzed during the current study, including patient-level clinical data as well as all sequencing data have been deposited and are publicly available in the cBioPortal for Cancer Genomics under the accession code ‘Histiocytosis Cobimetinib MSK, Nature 2019’ (<ext-link ext-link-type="uri" xlink:href="http://www.cbioportal.org/study?id=histiocytosis_cobi_msk_2019">http://www.cbioportal.org/study?id=histiocytosis_cobi_msk_2019</ext-link>).</p>
              </sec>
            </sec>
            <sec sec-type="extended-data" id="S12">
              <title>Extended Data</title>
              <fig id="F3" orientation="portrait" position="anchor">
                <label>Extended Data Figure 1.</label>
                <caption>
                  <title>Waterfall plot of maximum change in tumor size by RECIST following cobimetinib treatment in histiocytosis patients (n=14).</title>
                  <p id="P24">The upper and lower dotted lines represent cut-offs for progressive disease and partial response, respectively. Colors of bars indicate genomic alteration present. Notations above bars indicate specific mutation. One patient (asterisk) had prior BRAF inhibitor therapy that was discontinued due to intolerance. One patient (dagger) died due to underlying disease.</p>
                </caption>
                <graphic xlink:href="nihms-1521555-f0003"/>
              </fig>
              <fig id="F4" orientation="portrait" position="anchor">
                <label>Extended Data Figure 2.</label>
                <caption>
                  <title>PET-Defined Duration of Response (N=16).</title>
                  <p id="P25">Depicts the duration of response according to PET criteria in the 16 responding patients, beginning with date of initial response.</p>
                </caption>
                <graphic xlink:href="nihms-1521555-f0004"/>
              </fig>
              <fig id="F5" orientation="portrait" position="anchor">
                <label>Extended Data Figure 3.</label>
                <caption>
                  <title>Histopathology of histiocytoses with novel activating mutations in MEK2, RAF1, and BRAF treated on study.</title>
                  <p id="P26"><bold>(a)</bold> Protein diagram (top) and histological images (middle) demonstrating Erdheim-Chester disease (ECD) with a MAP2K2 Y134H mutation. <bold>(b)</bold> Protein diagram (top) and histological images (middle) demonstrating non-Langerhans cell histiocytosis with a RAF1 K106N mutation. <bold>(c)</bold> Protein diagram (top) and histological images (middle) demonstrating ECD with a BRAF N486_T491delinsK mutation.</p>
                </caption>
                <graphic xlink:href="nihms-1521555-f0005"/>
              </fig>
              <fig id="F6" orientation="portrait" position="anchor">
                <label>Extended Data Figure 4.</label>
                <caption>
                  <title>Study CONSORT diagram.</title>
                  <p id="P27">Shows the flow of patients through all phases of study participation from enrollment, follow-up, and data analysis.</p>
                </caption>
                <graphic xlink:href="nihms-1521555-f0006"/>
              </fig>
              <table-wrap id="T1" position="anchor" orientation="portrait">
                <label>Extended Data Table 1.</label>
                <caption>
                  <p id="P28">Demographic and Clinical Characteristics (N=18)</p>
                </caption>
                <table frame="box" rules="all">
                  <colgroup span="1">
                    <col align="left" valign="middle" span="1"/>
                    <col align="left" valign="middle" span="1"/>
                  </colgroup>
                  <thead>
                    <tr>
                      <th align="left" valign="top" rowspan="1" colspan="1">Characteristic</th>
                      <th align="center" valign="top" rowspan="1" colspan="1">Value, N (%)</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Age, Median (range) year</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">51.9 (18.3–79.5)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Sex</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Male</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">13 (72)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Female</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5 (28)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Histiocytosis type</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Erdheim-Chester disease</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">12 (67)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Rosai-Dorfman disease</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (11)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Langerhans cell histiocytosis</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (11)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Mixed histiocytosis</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (11)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Mitogen-activated protein kinase mutation</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> BRAF</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">  V600E</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4 (22)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">  N486_T491delinsK</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> MEK1</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">  Q56P</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">  P105_1107del</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">  P124L</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">  P124Q</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> ARAF</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">  S225V</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> RAF1 K106N</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> MEK2 Y134H</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> KRAS R149G</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> &gt;1 mutation</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">  BRAF V600E; NRAS G12D; KRAS G13C</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">  KRAS G12R; ARAF P216A</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Unknown</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3 (17)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">ECOG performance-status score</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> 0</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5 (28)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> 1</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">8 (44)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> 2</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (11)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> 3</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3 (17)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Central nervous system involvement</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Yes</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">9 (50)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> No</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">9 (50)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">No. of prior systemic therapies</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> 0</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (11)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> 1</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">6 (33)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> 2</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">8 (44)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> ≥3</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (11)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Prior systemic therapy</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Any prior therapy</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">16 (89)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Immunosuppression<sup><xref rid="TFN1" ref-type="table-fn">1</xref></sup></td>
                      <td align="center" valign="top" rowspan="1" colspan="1">12 (67)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Cytotoxic chemotherapy<sup><xref rid="TFN2" ref-type="table-fn">2</xref></sup></td>
                      <td align="center" valign="top" rowspan="1" colspan="1">9 (50)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Interferon-alpha</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5 (28)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Kinase inhibitor<sup><xref rid="TFN3" ref-type="table-fn">3</xref></sup></td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3 (18)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="TFN1">
                    <label>1-</label>
                    <p id="P29">Corticosteroids, anakinra, sirolimus, infliximab, intravenous immunoglobulin, rituximab.</p>
                  </fn>
                  <fn id="TFN2">
                    <label>2-</label>
                    <p id="P30">Methotrexate, cytarabine, cladribine, 6-mercaptopurine, vinblastine, lenolidamide, cyclophosphamide, etoposide.</p>
                  </fn>
                  <fn id="TFN3">
                    <label>3-</label>
                    <p id="P31">Vemurafenib, dasatinib.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <table-wrap id="T2" position="anchor" orientation="portrait">
                <label>Extended Data Table 2.</label>
                <caption>
                  <p id="P32">Overall Response Rate</p>
                </caption>
                <table frame="box" rules="all">
                  <colgroup span="1">
                    <col align="left" valign="middle" span="1"/>
                    <col align="left" valign="middle" span="1"/>
                    <col align="left" valign="middle" span="1"/>
                  </colgroup>
                  <thead>
                    <tr>
                      <th align="left" valign="top" rowspan="1" colspan="1">Response</th>
                      <th align="center" valign="top" rowspan="1" colspan="1">PET Response (N=18)</th>
                      <th align="center" valign="top" rowspan="1" colspan="1">RECIST Response (N=14)</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Overall response rate, % (90% one-sided Confidence Interval)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">89 (73–100)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">57 (37–100)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Best Response, N (%)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Complete</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">13 (72)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (14)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Partial</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3 (17)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">6 (43)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Stable</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5 (36)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Progressive</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1"> Not Evaluable</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (7)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="TFN4">
                    <p id="P33">Demonstrates the overall response rate, and best response (complete, partial, stable, progressive, non-evaluable) using both PET response criteria and RECIST version 1.1 criteria.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <table-wrap id="T3" position="anchor" orientation="portrait">
                <label>Extended Data Table 3.</label>
                <caption>
                  <p id="P34">Safety of cobimetinib in phase 2 study in histiocytosis patients</p>
                </caption>
                <table frame="box" rules="all">
                  <colgroup span="1">
                    <col align="left" valign="middle" span="1"/>
                    <col align="left" valign="middle" span="1"/>
                    <col align="left" valign="middle" span="1"/>
                    <col align="left" valign="middle" span="1"/>
                  </colgroup>
                  <thead>
                    <tr>
                      <th align="left" valign="top" rowspan="1" colspan="1"/>
                      <th align="center" valign="top" rowspan="1" colspan="1">Grade 1/2(%)</th>
                      <th align="center" valign="top" rowspan="1" colspan="1">Grade 3/4 (%)</th>
                      <th align="center" valign="top" rowspan="1" colspan="1">All (%)</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Rash<xref rid="TFN6" ref-type="table-fn">*</xref></td>
                      <td align="center" valign="top" rowspan="1" colspan="1">15 (83)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">15 (83)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Diarrhea</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">11 (61)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (11)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">13 (72)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Creatine phosphokinase elevation</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">10 (56)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">11 (61)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Hypomagnesemia</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">10 (56)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">10 (56)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Alkaline phosphatase increased</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">9 (50)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">9 (50)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">AST/ALT elevation</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">8 (44)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">8 (44)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Nausea</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">7 (39)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">7 (39)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Anemia</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4 (22)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (11)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">6 (33)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Dry skin</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5 (28)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5 (28)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Infection<sup><xref rid="TFN7" ref-type="table-fn">#</xref></sup></td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5 (28)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5 (28)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Vomiting</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5 (28)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5 (28)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Abdominal disturbance</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4 (22)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4 (22)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Edema limbs</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4 (22)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4 (22)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Fatigue</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4 (22)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4 (22)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Hyponatremia</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (11)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (11)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4 (22)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Anorexia</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3 (17)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3 (17)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Hypoalbuminemia</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3(17)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0(0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3(17)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Hypocalcemia</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3 (17)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3 (17)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Pruritus</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3 (17)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3 (17)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Serum amylase increased</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (11)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3 (17)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">White blood cell decreased</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3 (17)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3 (17)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Hypokalemia</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (11)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (11)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Lipase increased</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (11)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Lymphocyte count decreased</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Retinal vein occlusion</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="TFN5">
                    <label>◊</label>
                    <p id="P35">Adverse events listed here are those that were attributed by investigators as related to cobimetinib and occurred in at least 15% of patients, regardless of grade, or of any frequency, for grade ≥3.</p>
                  </fn>
                  <fn id="TFN6">
                    <label>*</label>
                    <p id="P36">Combines the following terms: Rash acneiform, rash maculo-papular.</p>
                  </fn>
                  <fn id="TFN7">
                    <label>#</label>
                    <p id="P37">Combines the following terms: bladder infection, bronchial infection, oral infection, tooth infection, upper respiratory infection, urinary tract infection, infections - other.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <table-wrap id="T4" position="anchor" orientation="portrait">
                <label>Extended Data Table 4.</label>
                <caption>
                  <p id="P38">Safety, Regardless of Attribution</p>
                </caption>
                <table frame="box" rules="all">
                  <colgroup span="1">
                    <col align="left" valign="middle" span="1"/>
                    <col align="left" valign="middle" span="1"/>
                    <col align="left" valign="middle" span="1"/>
                    <col align="left" valign="middle" span="1"/>
                  </colgroup>
                  <thead>
                    <tr>
                      <th align="left" valign="top" rowspan="1" colspan="1"/>
                      <th align="center" valign="top" rowspan="1" colspan="1">Grade 1/2, N (%)</th>
                      <th align="center" valign="top" rowspan="1" colspan="1">Grade ≥3, N (%)</th>
                      <th align="center" valign="top" rowspan="1" colspan="1">All, N (%)</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Hyperglycemia</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">15 (83)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">16 (89)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Infection</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">14 (78)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">15 (83)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Rash</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">15 (83)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">-</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">15 (83)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Hypoalbuminemia</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">14 (78)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">-</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">14 (78)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Diarrhea</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">11 (61)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (11)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">13 (72)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Anemia</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">9 (50)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (11)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">11 (61)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">CPK increased</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">10 (56)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">11 (61)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Hypomagnesemia</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">11 (61)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">-</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">11 (61)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Alkaline phosphatase increased</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">10 (56)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">-</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">10 (56)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Hypernatremia</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">10 (56)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">-</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">10 (56)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">AST/ALT increased</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">9 (50)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">10 (56)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Platelet count decreased</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">8 (44)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (11)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">10 (56)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">White blood cell decreased</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">7(39)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">8 (44)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Edema limbs</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">7(39)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">-</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">7(39)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Hypocalcemia</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5(28)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (11)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">7(39)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Lipase increased</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5(28)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (11)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">7(39)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Nausea</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">7(39)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">-</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">7(39)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Dry skin</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">6 (33)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">-</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">6 (33)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Fatigue</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5(28)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">-</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5(28)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Hyperkalemia</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4(22)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5(28)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Hypoglycemia</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5(28)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">-</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5(28)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Hyponatremia</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (11)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3(17)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5(28)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Neutrophil count decreased</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4(22)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5(28)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Serum amylase increased</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4(22)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5(28)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Vomiting</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5(28)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">-</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5(28)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Blood bilirubin increased</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4(22)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">-</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4(22)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Constipation</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4(22)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">-</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4(22)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Dyspnea</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3(17)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4(22)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Gastrointestinal symptoms</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4(22)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">-</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4(22)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Lymphocyte count decreased</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">-</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4(22)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4(22)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Pain</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3(17)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4(22)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Anorexia</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3(17)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">-</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3(17)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Creatinine increased</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3(17)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">-</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3(17)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Dry mouth</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3(17)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">-</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3(17)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Hypertriglyceridemia</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3(17)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">-</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3(17)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Hypokalemia</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (11)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3(17)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">INR increased</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (11)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3(17)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Pruritus</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3(17)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">-</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3(17)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="TFN8">
                    <label>◊</label>
                    <p id="P39">Adverse events listed here are those that occurred in at least 15% of patients, regardless of grade or investigator attribution. Infection combines the following terms: bladder infection, bronchial infection, oral infection, tooth infection, upper respiratory infection, urinary tract infection, infections and infestations - other. Rash combines: rash acneiform, rash maculo-papular.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <table-wrap id="T5" position="anchor" orientation="portrait">
                <label>Extended Data Table 5.</label>
                <caption>
                  <p id="P40">Genomic Testing Methodology</p>
                </caption>
                <table frame="box" rules="all">
                  <colgroup span="1">
                    <col align="left" valign="middle" span="1"/>
                    <col align="left" valign="middle" span="1"/>
                    <col align="left" valign="middle" span="1"/>
                    <col align="left" valign="middle" span="1"/>
                  </colgroup>
                  <thead>
                    <tr>
                      <th align="left" valign="top" rowspan="1" colspan="1">Study ID</th>
                      <th align="left" valign="top" rowspan="1" colspan="1">Histiocytosis</th>
                      <th align="left" valign="top" rowspan="1" colspan="1">MAPK Pathway Mutation</th>
                      <th align="left" valign="top" rowspan="1" colspan="1">Assays</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">ECD</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">ARAF S225V</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">WES, TES</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">2</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">RDD</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">No mutation identified</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">None</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">3</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">ECD</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">KRAS R149G</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">WES, TES</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">RDD</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">No mutation identified</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">WES, TES, TRS</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">5</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">ECD</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">BRAF V600E</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">PCR</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">6</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">ECD</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">BRAF V600E</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">TES, TRS, cfDNA</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">7</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">ECD</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">BRAF V600E</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">WES, PCR</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">8</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">ECD</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">BRAF V600E</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">PCR</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">9</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">LCH</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">BRAF N486_T491del</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">WES, TES, TRS</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">10</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Mixed Histiocytosis</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">RAF1 K106N</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">WES, TES, TRS</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">11</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Mixed Histiocytosis</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">MEK1 P124L</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">WES, TES, TRS, Sequenom</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">12</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">ECD</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">MEK1 P124Q</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">WES, TES, TRS</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">13</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">ECD</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">MEK1 Q56P</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">WES, TES</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">14</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">ECD</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">MEK1 P105_l107del</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">WES, TES</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">15</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">ECD</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">MEK2 Y134H</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">WES, TES, cfDNA</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">16</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">ECD</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">KRAS G12R / ARAF P216A</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">TES</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">17</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">LCH</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">BRAF V600E / NRAS G12D / KRAS G13C</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">TES</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">18</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">ECD</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">No mutation identified</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">WES, TES</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="TFN9">
                    <p id="P41">ECD: Erdheim-Chester disease; LCH: Langerhans cell histiocytosis; RDD: Rosai-Dorfman disease; CR: complete response; PR: partial response; SD: stable disease; TES: Targeted Exon Sequencing; TRS: Targeted RNA Sequencing; cfDNA: Cell-Free DNA; PCR; polymerase chain reaction; WES: Whole Exome Sequencing; NE: Not-Evaluable; NA: Not Applicable</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
            </sec>
            <sec sec-type="supplementary-material" id="SM1">
              <title>Supplementary Material</title>
              <supplementary-material content-type="local-data" id="SD1">
                <label>1</label>
                <media xlink:href="NIHMS1521555-supplement-1.docx" orientation="portrait" xlink:type="simple" id="d36e1838" position="anchor"/>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="SD2">
                <label>2</label>
                <media xlink:href="NIHMS1521555-supplement-2.pdf" orientation="portrait" xlink:type="simple" id="d36e1842" position="anchor"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="S13">
              <title>Acknowledgements</title>
              <p id="P42">We thank the patients and their families for participating in this study. This work was supported by Genentech and grants from the Histiocyte Society, the Erdheim-Chester Disease Global Alliance, the Functional Genomics Initiative of Memorial Sloan Kettering Cancer Center (MSKCC), the Society of Memorial Sloan Kettering Cancer Center, the Histiocytosis Association, the Translational and Integrative Medicine Award of Memorial Sloan Kettering Cancer Center, the Geoffrey Beene Center of MSKCC, the American Society of Hematology, the Leukemia &amp; Lymphoma Society, Frame Fund, Nonna’s Garden Foundation, and National Institutions of Health (P30 CA008748, 1 R01 CA201247, K08 CA218901).</p>
              <p id="P43">The authors report the following competing financial and non-financial interests: The authors declare the following competing interests: DLH: grants from Erdheim-Chester Disease Global Alliance, The Histiocytosis Association, the Society of Memorial Sloan Kettering, and the American Society for Clinic Oncology. BHD: grants from National Cancer Institute, American Society of Hematology, and Erdheim-Chester Disease Global Alliance Foundation. GU: personal fees from Sanofi and grants from Sanofi, Novartis, Genentech. RJY: personal fees from Agios, PUMA, NordicNeuroLabs and Icon, and grants from Agios. RR: personal fees from Incyte, Celgene, Agios, Jazz, BeyondSpring, Apexx, and Partner Therapeutics, and research funding from Stemline and Constellation. ML: personal fees and royalties from Roche/Genentech, and research funding from Veloce, Berg, US Biotest. AD: personal fees from Roche, Corvus Pharmaceuticals, Physicians’ Education Resource, Seattle Genetics, Peerview Institute, Oncology Specialty Group, Pharmacyclics, Celgene, and Novartis and grants from National Cancer Institute, Roche. NR: personal fees from Array BioPharma, Millennium Pharmaceuticals, AstraZeneca / MedImmune, Novartis, Eli Lilly, Boehringer Ingelheim, Merrimack Pharmaeutics, Chugai, Beigene, Daiichi Sankyo, Kura Oncology, ZAI Lab, F-Prime, and Kadmon and grants from Chugai, Bayer, and Tarveda. AI: personal fees from Mylan. OAW: grants from National Cancer Institute, National Heart Lung and Blood Institute, and H3B Biomedicine and personal fees from H3B Biomedicine, Foundation Medicine Inc, Merck, and Jansen. DMH: personal fees from Atara Biotherapeutics, Chugai Pharma, Boehringer Ingelheim, AstraZeneca, Pfizer, Bayer, Debiopharm Group, and Genetech, and grants from National Cancer Institute, AstraZeneca, Puma Biotechnology, and Loxo Oncology. The remaining authors have nothing to disclose.</p>
            </ack>
            <fn-group>
              <fn id="FN3">
                <p id="P44"><bold>Supplementary Information</bold> available online.</p>
              </fn>
              <fn id="FN4">
                <p id="P45"><bold>Reviewer Information</bold><italic>Nature</italic> thanks X and the other anonymous reviewer(s) for their contribution to the peer review of this work.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1</label>
                <mixed-citation publication-type="journal"><name><surname>Haroche</surname><given-names>J</given-names></name><etal/><article-title>Histiocytoses: emerging neoplasia behind inflammation</article-title>. <source>The Lancet. Oncology</source><volume>18</volume>, <fpage>e113</fpage>–<lpage>e125</lpage>, doi:<pub-id pub-id-type="doi">10.1016/S1470-2045(17)30031-1</pub-id> (<year>2017</year>).<pub-id pub-id-type="pmid">28214412</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2</label>
                <mixed-citation publication-type="journal"><name><surname>Allen</surname><given-names>CE</given-names></name>, <name><surname>Merad</surname><given-names>M</given-names></name> &amp; <name><surname>McClain</surname><given-names>KL</given-names></name>
<article-title>Langerhans-Cell Histiocytosis</article-title>. <source>The New England journal of medicine</source>
<volume>379</volume>, <fpage>856</fpage>–<lpage>868</lpage>, doi:<pub-id pub-id-type="doi">10.1056/NEJMra1607548</pub-id> (<year>2018</year>).<pub-id pub-id-type="pmid">30157397</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3</label>
                <mixed-citation publication-type="journal"><name><surname>Badalian-Very</surname><given-names>G</given-names></name><etal/><article-title>Recurrent BRAF mutations in Langerhans cell histiocytosis</article-title>. <source>Blood</source><volume>116</volume>, <fpage>1919</fpage>–<lpage>1923</lpage>, doi:<pub-id pub-id-type="doi">10.1182/blood-2010-04-279083</pub-id> (<year>2010</year>).<pub-id pub-id-type="pmid">20519626</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4</label>
                <mixed-citation publication-type="journal"><name><surname>Haroche</surname><given-names>J</given-names></name><etal/><article-title>High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses</article-title>. <source>Blood</source><volume>120</volume>, <fpage>2700</fpage>–<lpage>2703</lpage>, doi:<pub-id pub-id-type="doi">10.1182/blood-2012-05-430140</pub-id> (<year>2012</year>).<pub-id pub-id-type="pmid">22879539</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5</label>
                <mixed-citation publication-type="journal"><name><surname>Emile</surname><given-names>JF</given-names></name>, <name><surname>Charlotte</surname><given-names>F</given-names></name>, <name><surname>Amoura</surname><given-names>Z</given-names></name> &amp; <name><surname>Haroche</surname><given-names>J</given-names></name>
<article-title>BRAF mutations in Erdheim-Chester disease</article-title>. <source>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</source>
<volume>31</volume>, <fpage>398</fpage>, doi:<pub-id pub-id-type="doi">10.1200/JCO.2012.46.9676</pub-id> (<year>2013</year>).<pub-id pub-id-type="pmid">23248255</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6</label>
                <mixed-citation publication-type="journal"><name><surname>Hyman</surname><given-names>DM</given-names></name><etal/><article-title>Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations</article-title>. <source>N Engl J Med</source><volume>373</volume>, <fpage>726</fpage>–<lpage>736</lpage>, doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1502309</pub-id> (<year>2015</year>).<pub-id pub-id-type="pmid">26287849</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7</label>
                <mixed-citation publication-type="journal"><name><surname>Diamond</surname><given-names>EL</given-names></name><etal/><article-title>Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study</article-title>. <source>JAMA Oncol</source><volume>4</volume>, <fpage>384</fpage>–<lpage>388</lpage>, doi:<pub-id pub-id-type="doi">10.1001/jamaoncol.2017.5029</pub-id> (<year>2018</year>).<pub-id pub-id-type="pmid">29188284</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8</label>
                <mixed-citation publication-type="journal"><name><surname>Diamond</surname><given-names>EL</given-names></name><etal/><article-title>Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms</article-title>. <source>Cancer Discov</source><volume>6</volume>, <fpage>154</fpage>–<lpage>165</lpage>, doi:<pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-0913</pub-id> (<year>2016</year>).<pub-id pub-id-type="pmid">26566875</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9</label>
                <mixed-citation publication-type="journal"><name><surname>Brown</surname><given-names>NA</given-names></name><etal/><article-title>High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis</article-title>. <source>Blood</source><volume>124</volume>, <fpage>1655</fpage>–<lpage>1658</lpage>, doi:<pub-id pub-id-type="doi">10.1182/blood-2014-05-577361</pub-id> (<year>2014</year>).<pub-id pub-id-type="pmid">24982505</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10</label>
                <mixed-citation publication-type="journal"><name><surname>Chakraborty</surname><given-names>R</given-names></name><etal/><article-title>Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis</article-title>. <source>Blood</source><volume>124</volume>, <fpage>3007</fpage>–<lpage>3015</lpage>, doi:<pub-id pub-id-type="doi">10.1182/blood-2014-05-577825</pub-id> (<year>2014</year>).<pub-id pub-id-type="pmid">25202140</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>Emile</surname><given-names>JF</given-names></name><etal/><article-title>Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease</article-title>. <source>Blood</source><volume>124</volume>, <fpage>3016</fpage>–<lpage>3019</lpage>, doi:<pub-id pub-id-type="doi">10.1182/blood-2014-04-570937</pub-id> (<year>2014</year>).<pub-id pub-id-type="pmid">25150293</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12</label>
                <mixed-citation publication-type="journal"><name><surname>Nelson</surname><given-names>DS</given-names></name><etal/><article-title>Somatic activating ARAF mutations in Langerhans cell histiocytosis</article-title>. <source>Blood</source><volume>123</volume>, <fpage>3152</fpage>–<lpage>3155</lpage>, doi:<pub-id pub-id-type="doi">10.1182/blood-2013-06-511139</pub-id> (<year>2014</year>).<pub-id pub-id-type="pmid">24652991</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13</label>
                <mixed-citation publication-type="journal"><name><surname>Chakraborty</surname><given-names>R</given-names></name><etal/><article-title>Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis</article-title>. <source>Blood</source><volume>128</volume>, <fpage>2533</fpage>–<lpage>2537</lpage>, doi:<pub-id pub-id-type="doi">10.1182/blood-2016-08-733790</pub-id> (<year>2016</year>).<pub-id pub-id-type="pmid">27729324</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14</label>
                <mixed-citation publication-type="journal"><name><surname>Cohen Aubart</surname><given-names>F</given-names></name><etal/><article-title>Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)</article-title>. <source>Blood</source><volume>130</volume>, <fpage>1377</fpage>–<lpage>1380</lpage>, doi:<pub-id pub-id-type="doi">10.1182/blood-2017-03-771873</pub-id> (<year>2017</year>).<pub-id pub-id-type="pmid">28667012</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15</label>
                <mixed-citation publication-type="journal"><name><surname>Jacobsen</surname><given-names>E</given-names></name>, <name><surname>Shanmugam</surname><given-names>V</given-names></name> &amp; <name><surname>Jagannathan</surname><given-names>J</given-names></name>
<article-title>Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib</article-title>. <source>N Engl J Med</source>
<volume>377</volume>, <fpage>2398</fpage>–<lpage>2399</lpage>, doi:<pub-id pub-id-type="doi">10.1056/NEJMc1713676</pub-id> (<year>2017</year>).<pub-id pub-id-type="pmid">29236635</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16</label>
                <mixed-citation publication-type="journal"><name><surname>Gounder</surname><given-names>MM</given-names></name>, <name><surname>Solit</surname><given-names>DB</given-names></name> &amp; <name><surname>Tap</surname><given-names>WD</given-names></name>
<article-title>Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation</article-title>. <source>N Engl J Med</source>
<volume>378</volume>, <fpage>1945</fpage>–<lpage>1947</lpage>, doi:<pub-id pub-id-type="doi">10.1056/NEJMc1511490</pub-id> (<year>2018</year>).<pub-id pub-id-type="pmid">29768143</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17</label>
                <mixed-citation publication-type="journal"><name><surname>Diamond</surname><given-names>EL</given-names></name><etal/><article-title>Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease</article-title>. <source>Blood</source><volume>124</volume>, <fpage>483</fpage>–<lpage>492</lpage>, doi:<pub-id pub-id-type="doi">10.1182/blood-2014-03-561381</pub-id> (<year>2014</year>).<pub-id pub-id-type="pmid">24850756</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18</label>
                <mixed-citation publication-type="journal"><name><surname>Abla</surname><given-names>O</given-names></name><etal/><article-title>Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease</article-title>. <source>Blood</source><volume>131</volume>, <fpage>2877</fpage>–<lpage>2890</lpage>, doi:<pub-id pub-id-type="doi">10.1182/blood-2018-03-839753</pub-id> (<year>2018</year>).<pub-id pub-id-type="pmid">29720485</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19</label>
                <mixed-citation publication-type="journal"><name><surname>Allen</surname><given-names>CE</given-names></name>, <name><surname>Ladisch</surname><given-names>S</given-names></name> &amp; <name><surname>McClain</surname><given-names>KL</given-names></name>
<article-title>How I treat Langerhans cell histiocytosis</article-title>. <source>Blood</source>
<volume>126</volume>, <fpage>26</fpage>–<lpage>35</lpage>, doi:<pub-id pub-id-type="doi">10.1182/blood-2014-12-569301</pub-id> (<year>2015</year>).<pub-id pub-id-type="pmid">25827831</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20</label>
                <mixed-citation publication-type="journal"><name><surname>Eisenhauer</surname><given-names>EA</given-names></name><etal/><article-title>New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)</article-title>. <source>Eur J Cancer</source><volume>45</volume>, <fpage>228</fpage>–<lpage>247</lpage>, doi:<pub-id pub-id-type="doi">10.1016/j.ejca.2008.10.026</pub-id> (<year>2009</year>).<pub-id pub-id-type="pmid">19097774</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21</label>
                <mixed-citation publication-type="journal"><name><surname>Arnaud</surname><given-names>L</given-names></name><etal/><article-title>CNS involvement and treatment with interferon-alpha are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients</article-title>. <source>Blood</source><volume>117</volume>, <fpage>2778</fpage>–<lpage>2782</lpage>, doi:<pub-id pub-id-type="doi">10.1182/blood-2010-06-294108</pub-id> (<year>2011</year>).<pub-id pub-id-type="pmid">21239701</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22</label>
                <mixed-citation publication-type="journal"><name><surname>Rosen</surname><given-names>LS</given-names></name><etal/><article-title>A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors</article-title>. <source>Invest New Drugs</source><volume>34</volume>, <fpage>604</fpage>–<lpage>613</lpage>, doi:<pub-id pub-id-type="doi">10.1007/s10637-016-0374-3</pub-id> (<year>2016</year>).<pub-id pub-id-type="pmid">27424159</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>23</label>
                <mixed-citation publication-type="journal"><name><surname>Larkin</surname><given-names>J</given-names></name><etal/><article-title>Combined vemurafenib and cobimetinib in BRAF-mutated melanoma</article-title>. <source>N Engl J Med</source><volume>371</volume>, <fpage>1867</fpage>–<lpage>1876</lpage>, doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1408868</pub-id> (<year>2014</year>).<pub-id pub-id-type="pmid">25265494</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24</label>
                <mixed-citation publication-type="journal"><name><surname>Falchook</surname><given-names>GS</given-names></name><etal/><article-title>Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial</article-title>. <source>Lancet Oncol</source><volume>13</volume>, <fpage>782</fpage>–<lpage>789</lpage>, doi:<pub-id pub-id-type="doi">10.1016/S1470-2045(12)70269-3</pub-id> (<year>2012</year>).<pub-id pub-id-type="pmid">22805292</pub-id></mixed-citation>
              </ref>
              <ref id="R25">
                <label>25</label>
                <mixed-citation publication-type="journal"><name><surname>Pratilas</surname><given-names>CA</given-names></name><etal/><article-title>Genetic predictors of MEK dependence in non-small cell lung cancer</article-title>. <source>Cancer research</source><volume>68</volume>, <fpage>9375</fpage>–<lpage>9383</lpage>, doi:<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-2223</pub-id> (<year>2008</year>).<pub-id pub-id-type="pmid">19010912</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <label>26</label>
                <mixed-citation publication-type="journal"><name><surname>Solit</surname><given-names>DB</given-names></name><etal/><article-title>BRAF mutation predicts sensitivity to MEK inhibition</article-title>. <source>Nature</source><volume>439</volume>, <fpage>358</fpage>–<lpage>362</lpage>, doi:<pub-id pub-id-type="doi">10.1038/nature04304</pub-id> (<year>2006</year>).<pub-id pub-id-type="pmid">16273091</pub-id></mixed-citation>
              </ref>
              <ref id="R27">
                <label>27</label>
                <mixed-citation publication-type="journal"><name><surname>Gao</surname><given-names>Y</given-names></name><etal/><article-title>Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties</article-title>. <source>Cancer discovery</source><volume>8</volume>, <fpage>648</fpage>–<lpage>661</lpage>, doi:<pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-1452</pub-id> (<year>2018</year>).<pub-id pub-id-type="pmid">29483135</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <label>28</label>
                <mixed-citation publication-type="journal"><name><surname>Emery</surname><given-names>CM</given-names></name><etal/><article-title>MEK1 mutations confer resistance to MEK and B-RAF inhibition</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>106</volume>, <fpage>20411</fpage>–<lpage>20416</lpage>, doi:<pub-id pub-id-type="doi">10.1073/pnas.0905833106</pub-id> (<year>2009</year>).<pub-id pub-id-type="pmid">19915144</pub-id></mixed-citation>
              </ref>
              <ref id="R29">
                <label>29</label>
                <mixed-citation publication-type="journal"><name><surname>Cheng</surname><given-names>DT</given-names></name><etal/><article-title>Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology</article-title>. <source>The Journal of molecular diagnostics : JMD</source><volume>17</volume>, <fpage>251</fpage>–<lpage>264</lpage>, doi:<pub-id pub-id-type="doi">10.1016/j.jmoldx.2014.12.006</pub-id> (<year>2015</year>).<pub-id pub-id-type="pmid">25801821</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <label>30</label>
                <mixed-citation publication-type="journal"><name><surname>Durham</surname><given-names>BH</given-names></name><etal/><article-title>Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations</article-title>. <source>Blood</source>, doi:<pub-id pub-id-type="doi">10.1182/blood-2017-01-765107</pub-id> (<year>2017</year>).</mixed-citation>
              </ref>
              <ref id="R31">
                <label>31</label>
                <mixed-citation publication-type="journal"><name><surname>Zheng</surname><given-names>Z</given-names></name><etal/><article-title>Anchored multiplex PCR for targeted next-generation sequencing</article-title>. <source>Nat Med</source><volume>20</volume>, <fpage>1479</fpage>–<lpage>1484</lpage>, doi:<pub-id pub-id-type="doi">10.1038/nm.3729</pub-id> (<year>2014</year>).<pub-id pub-id-type="pmid">25384085</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
          <floats-group>
            <fig id="F1" orientation="portrait" position="float">
              <label>Figure 1:</label>
              <caption>
                <title>Efficacy of MEK1/2 inhibition with cobimetinib across molecular subtypes of histiocytoses.</title>
                <p id="P46"><bold>(a)</bold> Waterfall plot of the maximum change in tumor metabolism according to standardized uptake values (SUVs) measured by positron emission tomography (PET). Colors of bars indicate genomic alteration present. Notations above bars indicate specific mutation. One patient (dagger) died due to underlying disease prior to first response evaluation. The lower dotted lines represent cut-off for partial response. <bold>(b)</bold> Swimmer plot of outcomes in all 18 patients. <bold>(c)</bold> PET-Defined progression-free survival (n=18).</p>
              </caption>
              <graphic xlink:href="nihms-1521555-f0001"/>
            </fig>
            <fig id="F2" orientation="portrait" position="float">
              <label>Figure 2:</label>
              <caption>
                <title>Characterization of novel activating mutations in MEK2, RAF1, and BRAF and their dependence on ERK signaling in histiocytoses.</title>
                <p id="P47"><bold>(a)</bold> Coronal PET and fused PET/CT imaging of femurs showing characteristic femoral lesions of ECD from a MEK2 Y134H mutant ECD patient pre- and during cobimetinib treatment. <bold>(b)</bold> Western blot (left) and number of viable cells (right) following IL-3 withdrawal of Ba/F3 cells stably expressing an empty vector, wild-type (WT) MEK2, or MEK2 Y134H mutant (the average of n=3 biological replicates ± standard deviation (SD) is plotted). Calculation of <italic>p</italic>-values was performed using two-way ANOVA; ****<italic>p</italic>&lt;0.0001. <bold>(c)</bold> Axial fused PET/CT imaging showing skull lesions (arrow) pre- and during cobimetinib treatment in a patient with BRAF N486_T491delinsK mutant LCH. <bold>(d)</bold> Western blot (left) and number of viable cells (right) following IL-3 withdrawal of Ba/F3 cells stably expressing an empty vector, WT BRAF, or BRAF N486_T491delinsK mutant (the average of n=3 biological replicates ± SD is plotted). Calculation of <italic>p</italic>-values was performed using two-way ANOVA; ****<italic>p</italic>&lt;0.0001. <bold>(e)</bold> Axial fused PET/CT imaging showing sacral lesions (arrow) pre-and during cobimetinib treatment in a patient with mixed histiocytosis and a RAF1 K106N mutation. <bold>(f)</bold> Western blot (left) and number of viable cells (right) following IL-3 withdrawal of Ba/F3 cells stably expressing an empty vector, WT RAF1, or RAF1 K106N mutant (the average of n=3 biological replicates ± SD is plotted). Calculation of <italic>p</italic>-values was performed using two-way ANOVA; ****<italic>p</italic>&lt;0.0001. <bold>(g)</bold> IC<sub>50</sub> of cells from (b), (d), and (e) to 72 hours of cobimetinib. Each experiment was performed with n=3 biological replicates and average ± SD is plotted. The calculation of <italic>p</italic>-values utilized the Ordinary one-way ANOVA; **<italic>p</italic> &lt;0.01.</p>
              </caption>
              <graphic xlink:href="nihms-1521555-f0002"/>
            </fig>
          </floats-group>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
